{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:40:52Z","timestamp":1770187252539,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.07.003","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:41:48Z","timestamp":1753299708000},"page":"22-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["What Is the Optimal Perioperative Treatment for Variant Subtypes of Bladder Cancer?"],"prefix":"10.1016","volume":"12","author":[{"given":"Scott M.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.07.003_b0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy is invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.07.003_b0010","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.urolonc.2024.08.003","article-title":"Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: a systematic review and meta-analysis of randomized clinical trials","volume":"43","author":"Oscar-Thompson","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.07.003_b0015","series-title":"WHO classification of tumours: urinary and male genital tumours","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.euf.2025.07.003_b0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs \u2013 part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.07.003_b0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/JU.0000000000001855","article-title":"Pathological downstaging and survival outcomes associated with neoadjuvant chemotherapy for variant histology muscle invasive bladder cancer","volume":"206","author":"Chakiryan","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.07.003_b0030","doi-asserted-by":"crossref","first-page":"E325","DOI":"10.1111\/j.1464-410X.2012.11751.x","article-title":"Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer","volume":"111","author":"Meeks","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.07.003_b0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/BLC-240008","article-title":"Neoadjuvant cisplatin, gemcitabine, and docetaxel in sarcomatoid bladder cancer: clinical activity and whole transcriptome analysis","volume":"10","author":"Johnson","year":"2024","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2025.07.003_b0040","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/JU.0000000000003836","article-title":"Impact of divergent differentiation and\/or histological subtype of urothelial carcinoma on patient outcomes in the GETUG-AFU V05 VESPER trial","volume":"211","author":"Allory","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.07.003_b0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JU.0000000000003778","article-title":"Long-term oncological outcomes in patients diagnosed with nonmetastatic plasmacytoid variant of bladder cancer: a 20-year University of Texas MD Anderson Cancer Center experience","volume":"211","author":"Sood","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.07.003_b0050","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","article-title":"Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma","volume":"124","author":"Teo","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2025.07.003_b0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925002068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925002068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:58:52Z","timestamp":1770145132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925002068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2405456925002068"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.07.003","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Is the Optimal Perioperative Treatment for Variant Subtypes of Bladder Cancer?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}